SGLT2 Inhibition Updates 2021 - SGLT2 Inhibition in Cardiorenal Disease
Published: 20 July 2021
-
Views:
22509
-
Likes:
7
-
Views:
22509
-
Likes:
7
-
Up Next
-
1m 20sPart 6 | Session 1 Welcome and Introduction -
11m 2sPart 6 | Session 2 How do SGLT2 Inhibitors Bring About Cardiorenal Benefits? -
11m 24sPart 6 | Session 3 Totality of Evidence in Heart Failure -
11m 20sPart 6 | Session 4 Trial Results Coming Out Soon -
10m 55sPart 6 | Session 5 Heart Failure Guidelines -
14m 37sPart 6 | Session 6 Panel Discussion
-
1m 1sPart 7 | Session 1 Welcome and Introduction -
17m 18s -
11m 29sPart 7 | Session 3 Panel Discussion
-
11m 8sPart 8 | Session 1 Welcome and Introduction -
6m 43sPart 8 | Session 2 Soloist Trial Overview -
36m 32sPart 8 | Session 3 Discussion
-
50m 20s
-
25m 59s
-
53sPart 1 | Session 1 Welcome and Introduction Stefan Anker, Shelley Zieroth
-
10m 23sPart 1 | Session 2 SGLT2 Inhibitors for Patients with Diabetes and an Increased CV Risk: How The Success Story Started Bernard Zinman
-
9m 18sPart 1 | Session 3 SGLT2 Inhibitors: Evolution from Glucose Lowering to Cardiorenal Protection Milton Packer
-
12m 18sPart 1 | Session 4 SGLT2 Inhibitors in Cardiology Indications: The Data John JV McMurray
-
9m 38sPart 1 | Session 5 SGLT2 Inhibitors in Chronic Kidney Disease: The Data Katherine Tuttle
-
14m 38sPart 1 | Session 6 Panel Discussion Stefan Anker, Shelley Zieroth, Andrew JS Coats, Bernard Zinman, John JV McMurray, Katherine Tuttle
-
9m 39sPart 2 | Session 1 Place of SGLT2 Inhibitors in the Heart Failure Treatment Algorithm Andrew JS Coats
-
8m 1sPart 2 | Session 2 SGLT2 Inhibitors: Safety Considerations Gerasimos Filippatos
-
7m 39sPart 2 | Session 3 How to Use SGLT2 Inhibitors in Daily Practice Javed Butler
-
6m 58sPart 2 | Session 4 Panel Discussion Andrew JS Coats, Gerasimos Filippatos, Shelley Zieroth, Stefan Anker
-
3m 56sPart 3 | Session 1 Totality of Evidence for the Cardiorenal Patient Alice Cheng, Andrew JS Coats
-
50m 42sPart 3 | Session 2 Discussion Alice Cheng, Andrew JS Coats
-
1m 55sPart 4 | Session 1 Welcome and Introduction Shelley Zieroth, John Spertus
-
43mPart 4 | Session 2 KCCQ Score Overview and Discussion Shelley Zieroth, John Spertus
-
1m 11sPart 5 | Session 1 Welcome and Introduction Gerasimos Filippatos, Giuseppe Rosano
-
7m 5sPart 5 | Session 2 SGLT2i in the Elderly and Vulnerable Patients Gerasimos Filippatos
Overview
Organised with scientific co-chairs Stefan Anker and Andrew Coats, this event includes presentations and panel discussions with a host of international thought-leaders.
The SGLT2 Updates 2021 conference SGLT2 Inhibition in Cardiorenal Disease: Translating Evidence into Clinical Practice covers the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.
In addition to plenary sessions and satellite symposia the conference featured a number of Meet The Expert breakout sessions discussing the implications in treatment of specific patient subgroups including patients with comorbidities. Audience questions were submitted throughout and were addressed by the panel experts.
Educational Objectives
SGLT2 Inhibition in Cardiorenal Disease
- Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
- Apply findings from clinical trials into clinical practice
- Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
- Evaluate the safety and cardiorenal benefits of glucose-lowering agents
- Implement the new guidelines of the HFA of the ESC in clinical practice
Target Audience
- Cardiologists
- Nephrologists
- Endocrinologists
More from this programme
Part 1
State of the Art 1
Part 2
SGLT2 Inhibitors in Heart Failure: A Practical Approach
Part 3
Meet The Expert: Implications for Clinical Practice - Breakout 1
Part 4
Meet The Expert: Implications for Clinical Practice - Breakout 2
Part 5
Meet The Expert: Implications for Clinical Practice - Breakout 3
Part 6
State of the Art 2
Part 7
SGLT2 Inhibitors for Heart Failure: The New Standard of Care
Part 8
Meet The Expert: Implications for Clinical Practice - Breakout 4
Part 9
Meet The Expert: Implications for Clinical Practice - Breakout 5
Part 10
Meet The Expert: Implications for Clinical Practice - Breakout 6
Faculty Biographies
Giuseppe Rosano
Consultant Cardiologist and Professor of Cardiology (Hon)
Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London, UK where he is also the director of MSc Heart Failure.
His research interests focus on experimental and clinical pharmacology, heart failure, cardiac metabolism, diabetes and gender differences in cardiovascular diseases. Prof Rosano has been core member of the Cardiovascular Working Party of the European Medicines Agency and member of the Pricing and Reimbursement Committee of the Italian Drug Agency. He is the President-Elect of the Heart Failure Association Board (HFA), and Chairman of the Education Committee of the HFA. Prof Rosano is on the editorial board for European Journal of Heart Failure, European Heart Journal CV Pharmacotherapy, Cardiac Failure Reviews and Cardiovascular Diabetology. He has authored more than 500 peer…
Gerasimos Filippatos
Professor of Cardiology
Prof Gerasimos Filippatos is a Professor of Cardiology and Cardiologist at National and Kapodistrian University of Athens, Athens, GR.
He studied Medicine at the University of Patras, and earned his doctorate Cum Laude from the University of Athens.
Prof Filippatos is Past President of the Heart Failure Association (HFA) of the European Society of Cardiology and he has published over 600 articles in peer-reviewed journals and authored more than 30 book chapters.